Alternatives to AskRx

RxSpan MD is a genuinely well-disclosed service wrapped in marketing that undercuts it. The disclosure: four compounding pharmacies named with phone numbers, two lead physicians named with NPI numbers that verify as active MDs, flat pricing posted before any intake, both compounded and real FDA-approved brand GLP-1s on one platform, and oral capsules for anyone who won't inject. Compounded semaglutide is $249 a month and tirzepatide $329, with brand Zepbound at $1,069, Ozempic at $1,299 and Wegovy at $1,349. The marketing is the problem. Its testimonials still name a different company — one patient describes what she 'expected from CareGLP' — and the doctors quoted in them are not the clinicians the same page names as its medical team. The homepage is built around a board-certified plastic surgeon who founded the practice but is licensed in California only and isn't the prescriber. Its compounded prices also sit above the roster median, and the oral capsules cost the same or more than the injections.

Pallas Health removes the two things that usually cost a working parent the most time: it publishes every price before intake, and it runs care asynchronously in 43 of 50 states, so there's no video appointment to wedge into a workday. Compounded semaglutide averages about $199 a month and tirzepatide $299, and unusually the genuine FDA-approved pens sit alongside them — Zepbound $1,069, Ozempic $1,299, Wegovy and Mounjaro $1,349 — all cash-pay from the same clinician. The price is flat at every dose, so a titration never produces a surprise bill, and the plan figure already contains the clinician, dose adjustments, check-ins and messaging with no membership fee. Its cancellation terms are unusually concrete: cancel free through the portal, keep access to the end of the paid period, full refund if a clinician declines you, and a $5 processing fee on a qualifying refund. The trade-offs are that billing lands every 12 weeks in $597 and $897 blocks rather than monthly, the compounding pharmacy is never named, and insurance is never billed.

The widest menu on this list — injections, lozenges, drops and a brand-name lane — with a flat price that genuinely holds as your dose climbs. The catch is the exit: every plan locks you in for two months.

The brand-access marketplace: real FDA-approved pens and oral options with insurance-style navigation — but a required video visit, a 28-day billing cycle, and prices that sit well above the compounded field.

A fast, fully async start with a needle-free sublingual tirzepatide option and — a genuine upgrade since our last check — flat pricing stated in writing. The catch is a state list it still won't publish.

Async-first compounded GLP-1 with a rarity for this list — free health coaching — at a flat one-price-all-doses rate. Fast and friendly up front; the strict, non-refundable fine print is the trade-off.

The posted price is half the bill, and the site says so itself. Read live on 26 August 2026, the weight-loss catalog is ten FDA-approved brand listings — Wegovy as a pill and a pen, Zepbound as a vial and a KwikPen, Ozempic in both forms, Mounjaro, and two new oral tablets in the Ozempic Pill and Foundayo — and every single one carries the same footnote: the figure covers medication only, and a membership at $39 for the first month then $149 a month is required and billed separately. So the $149 Wegovy Pill is really about $298 a month and the $299 Zepbound vial is about $448. That membership is not nothing — 24/7 messaging with licensed providers, monthly care-team follow-ups, a smart scale and named in-house clinicians — but it is $1,788 a year on top of the drug. One oddity to open before you buy: Mounjaro and one of two Zepbound listings are posted at a flat $1,899 a month on the same page as Zepbound vials at $299, and nothing explains the gap. Its FAQ asks whether video visits are required and whether all states are served, but keeps both answers inside collapsed panels, so neither could be verified. It carries two FDA warning letters dated 9 September 2025 over the compounded-semaglutide business it has since left behind entirely.

The widest menu on the board — compounded, oral and four brand pens, all on a chat visit with no camera — sold behind a pricing page that quotes you a monthly figure for a plan you have to pay for a year in advance.

Compounded semaglutide at $199 a month and tirzepatide at $299, the same price at every dose, and the daily tablet costs the same as the injection on both — all of it on an open pricing page you reach without a quiz. Brand-name prices are published too, which is rare: Wegovy $999, Ozempic $899, Mounjaro $999, cash. Two things to know before you enter a card. The badge at the top of every page says no subscription, and its own FAQ then asks whether you can cancel your subscription and tells you to call before your next billing date — so it does recur, whatever the badge says. And nothing anywhere on the site says how many weeks of medication one $199 charge actually buys. It ships to all 50 states, and it carries a June 2026 FDA warning letter for false or misleading claims, which it has since fixed.